Loading…

Interleukin‐22 serum levels are elevated in active scleritis

Purpose To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study. Methods The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to det...

Full description

Saved in:
Bibliographic Details
Published in:Acta ophthalmologica (Oxford, England) England), 2016-09, Vol.94 (6), p.e395-e399
Main Authors: Sainz‐de‐la‐Maza, Maite, Molins, Blanca, Mesquida, Marina, Llorenç, Victor, Zarranz‐Ventura, Javier, Sala‐Puigdollers, Anna, Matas, Jessica, Adan, Alfredo, Foster, C. Stephen
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33
cites cdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33
container_end_page e399
container_issue 6
container_start_page e395
container_title Acta ophthalmologica (Oxford, England)
container_volume 94
creator Sainz‐de‐la‐Maza, Maite
Molins, Blanca
Mesquida, Marina
Llorenç, Victor
Zarranz‐Ventura, Javier
Sala‐Puigdollers, Anna
Matas, Jessica
Adan, Alfredo
Foster, C. Stephen
description Purpose To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study. Methods The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and >2+), and associated systemic disease. Results Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls. Conclusion In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis.
doi_str_mv 10.1111/aos.13005
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1819142213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1819142213</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</originalsourceid><addsrcrecordid>eNqN0MtKw0AUBuBBFFurC19AAm50kXbumdkIpXgpFLpQwV2YJCeQmiZ1JlG68xF8Rp_EqaldCIJnc87i44fzI3RK8JD4GZnaDQnDWOyhPomECFkk1f7uFk89dOTcAmNJpOSHqEcjjDVTtI-uplUDtoT2uag-3z8oDRzYdhmU8AqlC4yFAPxtGsiCogpM2hSvELi0BFs0hTtGB7kpHZxs9wA93lw_TO7C2fx2OhnPwpRrIkLNaQ5KkogTyYWWIqWJzgjVBifAowg0JjqJMpZkOdUMeCK4wSrNJKgcA2MDdNHlrmz90oJr4mXhUihLU0HdupgoogmnlPyLCqlwJLCn57_oom5t5R_ZKK6YFEx5ddmp1NbOWcjjlS2Wxq5jguNN_7HvP_7u39uzbWKbLCHbyZ_CPRh14K0oYf13Ujye33eRX6A1jSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1814836538</pqid></control><display><type>article</type><title>Interleukin‐22 serum levels are elevated in active scleritis</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Sainz‐de‐la‐Maza, Maite ; Molins, Blanca ; Mesquida, Marina ; Llorenç, Victor ; Zarranz‐Ventura, Javier ; Sala‐Puigdollers, Anna ; Matas, Jessica ; Adan, Alfredo ; Foster, C. Stephen</creator><creatorcontrib>Sainz‐de‐la‐Maza, Maite ; Molins, Blanca ; Mesquida, Marina ; Llorenç, Victor ; Zarranz‐Ventura, Javier ; Sala‐Puigdollers, Anna ; Matas, Jessica ; Adan, Alfredo ; Foster, C. Stephen</creatorcontrib><description>Purpose To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study. Methods The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and &gt;2+), and associated systemic disease. Results Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls. Conclusion In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis.</description><identifier>ISSN: 1755-375X</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/aos.13005</identifier><identifier>PMID: 27009382</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; biomarker ; Case-Control Studies ; Cytokines ; Cytokines - blood ; Enzyme-Linked Immunosorbent Assay ; Female ; Health risk assessment ; Humans ; Interleukin-22 ; Interleukins - blood ; Male ; Middle Aged ; Ophthalmology ; Prospective Studies ; scleritis ; Scleritis - blood ; Scleritis - diagnosis ; Systemic diseases</subject><ispartof>Acta ophthalmologica (Oxford, England), 2016-09, Vol.94 (6), p.e395-e399</ispartof><rights>2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley &amp; Sons Ltd</rights><rights>2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2016 Acta Ophthalmologica Scandinavica Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</citedby><cites>FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27009382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sainz‐de‐la‐Maza, Maite</creatorcontrib><creatorcontrib>Molins, Blanca</creatorcontrib><creatorcontrib>Mesquida, Marina</creatorcontrib><creatorcontrib>Llorenç, Victor</creatorcontrib><creatorcontrib>Zarranz‐Ventura, Javier</creatorcontrib><creatorcontrib>Sala‐Puigdollers, Anna</creatorcontrib><creatorcontrib>Matas, Jessica</creatorcontrib><creatorcontrib>Adan, Alfredo</creatorcontrib><creatorcontrib>Foster, C. Stephen</creatorcontrib><title>Interleukin‐22 serum levels are elevated in active scleritis</title><title>Acta ophthalmologica (Oxford, England)</title><addtitle>Acta Ophthalmol</addtitle><description>Purpose To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study. Methods The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and &gt;2+), and associated systemic disease. Results Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls. Conclusion In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>biomarker</subject><subject>Case-Control Studies</subject><subject>Cytokines</subject><subject>Cytokines - blood</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Interleukin-22</subject><subject>Interleukins - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmology</subject><subject>Prospective Studies</subject><subject>scleritis</subject><subject>Scleritis - blood</subject><subject>Scleritis - diagnosis</subject><subject>Systemic diseases</subject><issn>1755-375X</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqN0MtKw0AUBuBBFFurC19AAm50kXbumdkIpXgpFLpQwV2YJCeQmiZ1JlG68xF8Rp_EqaldCIJnc87i44fzI3RK8JD4GZnaDQnDWOyhPomECFkk1f7uFk89dOTcAmNJpOSHqEcjjDVTtI-uplUDtoT2uag-3z8oDRzYdhmU8AqlC4yFAPxtGsiCogpM2hSvELi0BFs0hTtGB7kpHZxs9wA93lw_TO7C2fx2OhnPwpRrIkLNaQ5KkogTyYWWIqWJzgjVBifAowg0JjqJMpZkOdUMeCK4wSrNJKgcA2MDdNHlrmz90oJr4mXhUihLU0HdupgoogmnlPyLCqlwJLCn57_oom5t5R_ZKK6YFEx5ddmp1NbOWcjjlS2Wxq5jguNN_7HvP_7u39uzbWKbLCHbyZ_CPRh14K0oYf13Ujye33eRX6A1jSg</recordid><startdate>201609</startdate><enddate>201609</enddate><creator>Sainz‐de‐la‐Maza, Maite</creator><creator>Molins, Blanca</creator><creator>Mesquida, Marina</creator><creator>Llorenç, Victor</creator><creator>Zarranz‐Ventura, Javier</creator><creator>Sala‐Puigdollers, Anna</creator><creator>Matas, Jessica</creator><creator>Adan, Alfredo</creator><creator>Foster, C. Stephen</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>201609</creationdate><title>Interleukin‐22 serum levels are elevated in active scleritis</title><author>Sainz‐de‐la‐Maza, Maite ; Molins, Blanca ; Mesquida, Marina ; Llorenç, Victor ; Zarranz‐Ventura, Javier ; Sala‐Puigdollers, Anna ; Matas, Jessica ; Adan, Alfredo ; Foster, C. Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>biomarker</topic><topic>Case-Control Studies</topic><topic>Cytokines</topic><topic>Cytokines - blood</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Interleukin-22</topic><topic>Interleukins - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmology</topic><topic>Prospective Studies</topic><topic>scleritis</topic><topic>Scleritis - blood</topic><topic>Scleritis - diagnosis</topic><topic>Systemic diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sainz‐de‐la‐Maza, Maite</creatorcontrib><creatorcontrib>Molins, Blanca</creatorcontrib><creatorcontrib>Mesquida, Marina</creatorcontrib><creatorcontrib>Llorenç, Victor</creatorcontrib><creatorcontrib>Zarranz‐Ventura, Javier</creatorcontrib><creatorcontrib>Sala‐Puigdollers, Anna</creatorcontrib><creatorcontrib>Matas, Jessica</creatorcontrib><creatorcontrib>Adan, Alfredo</creatorcontrib><creatorcontrib>Foster, C. Stephen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sainz‐de‐la‐Maza, Maite</au><au>Molins, Blanca</au><au>Mesquida, Marina</au><au>Llorenç, Victor</au><au>Zarranz‐Ventura, Javier</au><au>Sala‐Puigdollers, Anna</au><au>Matas, Jessica</au><au>Adan, Alfredo</au><au>Foster, C. Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin‐22 serum levels are elevated in active scleritis</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><addtitle>Acta Ophthalmol</addtitle><date>2016-09</date><risdate>2016</risdate><volume>94</volume><issue>6</issue><spage>e395</spage><epage>e399</epage><pages>e395-e399</pages><issn>1755-375X</issn><eissn>1755-3768</eissn><abstract>Purpose To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study. Methods The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and &gt;2+), and associated systemic disease. Results Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls. Conclusion In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27009382</pmid><doi>10.1111/aos.13005</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1755-375X
ispartof Acta ophthalmologica (Oxford, England), 2016-09, Vol.94 (6), p.e395-e399
issn 1755-375X
1755-3768
language eng
recordid cdi_proquest_miscellaneous_1819142213
source Wiley-Blackwell Read & Publish Collection
subjects Adult
Aged
Aged, 80 and over
biomarker
Case-Control Studies
Cytokines
Cytokines - blood
Enzyme-Linked Immunosorbent Assay
Female
Health risk assessment
Humans
Interleukin-22
Interleukins - blood
Male
Middle Aged
Ophthalmology
Prospective Studies
scleritis
Scleritis - blood
Scleritis - diagnosis
Systemic diseases
title Interleukin‐22 serum levels are elevated in active scleritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A54%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin%E2%80%9022%20serum%20levels%20are%20elevated%20in%20active%20scleritis&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=Sainz%E2%80%90de%E2%80%90la%E2%80%90Maza,%20Maite&rft.date=2016-09&rft.volume=94&rft.issue=6&rft.spage=e395&rft.epage=e399&rft.pages=e395-e399&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/aos.13005&rft_dat=%3Cproquest_cross%3E1819142213%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1814836538&rft_id=info:pmid/27009382&rfr_iscdi=true